Illinois · Nonprofit
AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY
AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY (Illinois) receives grants from 3 organizations whose IRS filings report $70,000 to it, the largest being GABRIELLE'S ANGEL FOUNDATION FOR CANCER RESEARCH INC ($30,000). 0 of them have funded it in more than one year.
- Revenue FY2024
- $8.5M
- Funders on record
- 3
- Grants received
- $70k
- Net assets
- $9.2M
What American Society for Transplantation & Cellular Therapy does
Mission
Astct is an international professional membership association of more than 3000 physicians, investigators and other health care professionals from more than 45 countries, who are dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. Astct strives to be the leading organization promoting research, education and clinical practice in the field through promoting: comprehensive development and advancement of the field of blood and marrow transplantation; excellence in clinical care and treatment outcomes through standards for blood and marrow transplantation; innovative research to advance the science and clinical applications of other cellular therapies; and, rapid dissemination of basic and clinical bmt research findings within the medical field and to the general public.
As stated on its FY2024 Form 990.
Programs
Annual meeting - astct typically holds a general meeting with the center for international blood and marrow transplant research ("cibmtr"), where administrators, clinicians, data manager/clinical research professionals, fellows in training, investigators, laboratory technicians, medical doctors, nurses, nurse practitioners, pharmacists, physician assistants, and other allied health professionals benefit from a full scientific program; addressing the most timely issues in hematopoietic cell transplantation and cellular therapy.
$2,529,946 spentof which $15,220 as grants$1,932,433 earned by the program34% of program spendingEducation and conferences - astct provides focused education to improve research, patient outcomes, and foster professional development through diverse outlets and opportunities.
$1,646,966 spentof which $4,500 as grants$259,751 earned by the program22% of program spendingOther programs - throughout the year, astct offers sponsorships in support of various functions, including its content hub. Sponsorship are recognized ratably over the appliable period. Astct also receives a limited amount of revenues from activities, which are recognized at a point in time in which the related performance obligations are fulfilled.
$1,170,764 spentof which $101,215 as grants$816,064 earned by the program16% of program spendingJournal and publications - astct receives royalties on advertisement sales and other sources of revenue associated with its journal, transplantation and cellular therapy, as well as certain editorial subsidies, under a collaborative arrangement with elsevier, inc.
$369,935 spentof which $10,000 as grants$509,967 earned by the program5% of program spendingMembership - astct members span the entire field of transplantation and cellular therapy - from basic science research to direct patient care. Astct offers a variety of membership types; including affiliate, joint, associate, honorary, in-training, international, and institutional.
$236,424 spent$278,668 earned by the program3% of program spendingPolicy and legislative - astct proudly advocates on behalf of its members and patients by engaging with government leaders on capitol hill and submitting responses to important legislative and policy changes. Astct believes that advocacy is a key component in serving patients by helping them to access some of the most innovative lifesaving treatments
$691,933 spent9% of program spendingIndustry support - astct sponsors "new investigator awards" as part of its industry relation program designed to encourage clinical and/or laboratory research by young investigators in the field of blood and marrow transplantation, and/or cell therapy.
$800,000 spentof which $800,000 as grants$1,288,995 earned by the program11% of program spending
The 7 programs described on its FY2023 Form 990, listed largest first by expense. Program spending in total: $7,445,968.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2023 to 2024, from $12M to $14M (+16%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
33% of AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY’s revenue is contributions — about as donation-reliant as the typical peer (51% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 2 of the last 7 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Who funds it, year by year
Grant support over time, funder by funder — shade shows the grant size each year.
From the IRS filings of AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY leans on a few funders — its largest provides 43% of grant income and the top three 100%; half comes from just 2 funders.
the vertical line marks half of all grant income — 2 funders to its left
100% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Where its funders are
AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY draws 100% of its grant income from funders outside Illinois, across 3 states in all.
Funder states come from each funder’s own filing. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY has grown faster than half of the 8,121 health nonprofits its size.
this organization peer median middle 50% of peers· 8,121 health nonprofits $1M–$10M, FY2024
Organizations like AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Illinois
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
93% of spending goes to programs.
Governance
Public support
80%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 1 state
Screen this organization
A dated, signed PDF of the compliance screen for AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY?
- AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY (Illinois) receives grants from 3 organizations whose IRS filings report $70,000 to it, the largest being GABRIELLE'S ANGEL FOUNDATION FOR CANCER RESEARCH INC ($30,000). 0 of them have funded it in more than one year.
- How many funders does AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY have?
- IRS filings report 3 organizations giving $70,000 in grants to AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY.
- Who is the largest funder of AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY?
- GABRIELLE'S ANGEL FOUNDATION FOR CANCER RESEARCH INC is the largest funder on record, with $30,000 in grants. The full list of funders is on this page.
- How can an organization like AMERICAN SOCIETY FOR TRANSPLANTATION & CELLULAR THERAPY find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Illinois. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 3 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing